Michael Kyriakides is an Investment Partner at Syncona, a life sciences investor focused on founding, building and funding companies. He works closely portfolio companies Freeline Therapeutics, Purespring Therapeutics and Clade Therapeutics. He is also a non-executive director of the board of Purespring Therapeutics and an observer to the board of Clade Therapeutics. Previously, Michael was a member of the Life Sciences team at L.E.K. Consulting and was involved in projects for pharmaceutical, biotech and private equity clients. Prior to joining L.E.K. Consulting, he was a clinical project and NMR manager in the Faculty of Medicine at Imperial College London. Michael obtained his doctorate degree in toxicology and metabolic profiling at Imperial College London.

Tom has 25 years’ experience in commercial real estate and heads up Savills UK Science group. He specialises in advising science related occupiers needing R&D, lab and manufacturing space, as well as landlords and developers looking to deliver specialist science related space across the UK.

Tom has advised on the acquisition of more than 600,000 sq ft of space over the last 3 years for the likes of Autolus, Quell Therapeutics, DNAe, Achilles Therapeutics, Avacta, Freeline Therapeutics and Omass.

Tim leads the science business area, across the UKIMEA region for Arup. He leads on strategy and

business development, maintains relationships with clients and manages a portfolio of projects.

Tim is a chartered engineer and experienced team leader, having led multi-discipline teams in

delivering engineering solutions on complex highly serviced buildings from concept design phases

through to fully coordinated detail design and construction.

He has been involved in science buildings from his first project over 28 years ago, working on the

design and construction of a facility to produce injectable vaccines. As well as other manufacturing

projects experience, Tim has been involved in the design of many research and development

laboratories for a range of science users and scales of project. These have been for private clients,

government institutes and higher education establishments.

Tim thrives in solving client’s challenges bringing a wealth of experience to provide robust, energy

efficient and sustainable design solutions, applying his knowledge of construction, commissioning

and maintenance.

Leading the UK R&D Estates Development function at AstraZeneca responsible for the development and execution of a Strategic Estates Masterplan.

Responsible for the development of a capital masterplan which delivers the Strategic Estates Masterplan; ensure the identification, scoping, senior leadership review and decision making (capital approval/timing/delivery process) and progression of major R&D building projects required

Responsible for the transition of any new capital projects into operational readiness, leading a world class Operational Readiness, transition and soft landings process

Anna Strongman is CEO of Oxford University Development (OUD), a joint

venture between Oxford University and Legal & General set up to build

Innovation Districts and subsidised accommodation for graduate students

and the university workforce.

Anna was previously Managing Partner of Argent LLP in London, where

she spent 12 years executing a range of asset, development, and business

planning projects. Highlights included leading the Asset Management of

King’s Cross, developing Coal Drops Yard, and setting up a BTR portfolio

with JV partners Related. Anna was instrumental in building the business

from 40 people to a team of 200 over a ten-year period and led the

corporate side of the business as Managing Partner.

Before joining Argent, Anna worked in the planning and economic development team of Arup, worked for DTZ

in Scotland, and lived for 18 months in Japan, where she studied Japanese and conducted research at the Japan

Productivity Centre as a Daiwa Scholar.

Rob is a Design Director at AKT II, responsible for leading a diverse range of projects, both in the UK and internationally, requiring a holistic focus across the many facets of design.

Rob has led many of the practices most complex mixed use developments, with a keen motivation for the higher education and research sector, which has seen him lead some of the UK’s most notable research developments including the Francis Crick Institute, UCL East and Merck’s new European HQ at Belgrove House.

Rob is a leading voice in how cities and buildings can accommodate future trends where the disciplines of life science, education and research combine with the already changing landscape of workplace design, to produce evolving innovation districts critical to the economic future of London and beyond.

As head of Mace’s Life Sciences Construction business, Rob leads on large-scale, award-winning projects including AstraZeneca’s global R&D Centre in Cambridge, St Bartholomew’s and London Hospitals and Jaguar Land Rover’s manufacturing capability. Most recently developers Oxford University and investor L&G appointed Rob to deliver two new buildings at Begbroke Science park.

Rob works closely with multidisciplinary project teams and the science community to deliver pioneering facilities that enable clients to compete for the best researchers, scientists, and funding.

Reka is the cofounder and Chief Operating Officer of Multus. She has a background in Biological Sciences specialising in Synthetic Biology from Imperial College London. She is dedicated to making a positive impact in the world, which she combined with her interests in the different fields of Biology and cofounded Multus to unlock the cultivated meat industry through targeting the critical bottleneck of growth media.

Ivana Poparic is Head of Cluster Development at MedCity, an organisation representing London’s world-leading health and life sciences cluster and part of the London & Partners family. She leads a team supporting the development of new life sciences infrastructure to attract more inward investment and research into London region. Her team helps life sciences organisations to find right R&D and manufacturing spaces in London and works with developers, investors and local government to facilitate development of new life sciences spaces and city’s innovation districts.

Ivana has extensive scientific and commercial expertise across the innovation pathway for drugs, devices, and digital technologies. Following a PhD in Human Genetics, her experience includes academic research, technology transfer, clinical research management, business development and investment roles.

Claire joined Stanhope in September 2018 from Grosvenor Britain & Ireland where lead the Asset

Management team for the Belgravia portfolio. There she was accountable for delivering the long term

strategy to create distinctive and vibrant neighbourhoods which attract footfall, spend and offer

prosperity to their tenants. Having moved around the Grosvenor business over ten years, and setting

up the London Estate investment team, she has stakeholder management expertise, strategic

planning experience, major change credentials and can point to significant operational success

heading a £1bn business.

Claire leads the Asset Management team at Stanhope, a portfolio of just under 3 million sq ft and

£2.5bn of assets under management. Most notably, Claire has focused on the recently transformed

White City area to deliver the strategic vision and further build on the areas commercial success and

established reputation as a vibrant, innovative and creative part of London.

Claire is a member of Real Estate Balance and a Mentor for Stanhope initiative Mentoring Circle.

John has played a key role in the evolution of the College's Financial Strategy since 2000 including the establishment of the College's Endowment Fund which now stands at just over half a billion pounds including the development of the Non-Core property portfolio (£8m in 2005 to £130m+ in 2022).

The strategic objective is to maintain a viable financial strategy for the College to achieve its long term growth ambitions.

John initiated the Imperial White City Campus, leading the College's acquisition of the various land assets and supporting consents for over 4 million sq ft of mixed use development to date.

This includes the development of the GradPad Postgraduate student accommodation portfolio; The I-Hub co-location operation in White City; the delivery of 88 Wood Lane and sale and development agreement for Centre House to create a Westmont with a meaningful allocation of apartments for College Key Workers.

Most recently John led the Scale Space Joint Venture to expand into digital and FinTech co-location and supported the joint Industrial Strategy with Hammersmith and Fulham.

This has created the critical foundations to deliver a genuine and inclusive Academic led White City Innovation District.

Mitchell Frizelle is the Laboratory Manager at Engitix Therapeutics, a biotechnology company utilising the unharnessed power of the ECM to accelerate drug discovery.

Colin advises clients throughout their lifecycle (all the way from start-up/spin-out to multinational listed companies) on the commercialisation of their intellectual property rights. In particular, advising on licensing deals, collaborations and R&D projects, distribution and manufacturing and the IP, commercial and regulatory aspects of M&A, VC investments and IPOs. Having a 1st class degree in Cell Biology his practice has naturally become focused on the life sciences, healthcare and technology (with a particular focus on med-tech and clean-tech) sectors. Colin is co-head of our Life Sciences Real Estate group.

Lauren is a Partner in the Real Estate team. She co-heads Taylor Wessing's life sciences real estate sector and sits on the ULI life science & healthcare council. Lauren’s recent experience includes advising life sciences occupiers in respect of their property portfolios, including lab and office space. Lauren has led on landmark transactions in the UK and advises on all matters related to commercial real estate; specialising in investment and development, and advising corporate occupiers.

Orestis Tzortzoglou joined BioMed in 2016 and currently serves as Vice President, Development, UK

Market. Orestis has been an integral part of BioMed Realty’s portfolio expansion in the U.K. In response

to significant tenant demand in Cambridge, the Company has assembled a pipeline that will deliver up to

1 million square feet of additional Class A space for life science companies.

Prior to joining BioMed, Orestis held development roles at London & Regional and Development

Securities Plc. Orestis received a Bachelor Degree in Business Administration and Finance from the ATEI

University of Athens and a Master of Science Degree from City University of London. He is an RICS

Chartered Surveyor.

Jenny is a director of development and construction at ARC where she is actively working with the greater ARC team to bring forward millions of square feet of cluster-based development focused on science and innovation. Jenny has spent the majority of her 15-year career focused on commercial life science development; 10 years of that working in America for the largest life science-focused REIT, Alexandria Real Estate, and a further year and a half in the UK as a consultant working for JLL advising developer clients on this niche asset class and its associated commercial opportunities. Jenny is passionate about the life science industry and the role that real estate partnership, both in design and in operation, can play as an enabler for growth at scale as the UK looks to establish itself as a science superpower in the coming decade.

Sam is a Design and Development Director at Reef Group, a pioneering developer with a strong portfolio in the Life Sciences sector. A qualified Architect with over 20 years of experience delivering awarding winning buildings and places Sam leads many of Reef Groups science and technology projects in London and the UK including Cavendish Square, a unique healthcare-led development at the entrance to Harley Street in Westminster. Recent projects Sam has led include the design of a life sciences campus at the Westbrook Centre in Cambridge and a soon to complete technology campus in the City of Gloucester. Prior to joining Reef he designed and delivered many commercial projects including London Wall Place in the City of London and a number of secondary and higher education projects whilst teaching at schools of architecture including Cambridge and the Architectural Association.

Artem founded Mission Street in 2017. Building on extensive track record across investment, development and finance, he has overall strategic responsibility for the growth of the company, project delivery and management.

Prior to Mission Street, Artem was Head of UK Acquisitions and a member of the founding team of GreenOak Real Estate (now BGO), a major international real estate investment and asset management firm (at the time c. £10 Bn under management). He also previously worked for Morgan Stanley in their UK Real Estate team.

Artem’s track record spans development, asset management, real estate private equity and finance. This has included property acquisitions and corporate M&A, leading end-to-end delivery of complex development and asset management projects across the UK, and structuring debt and equity financing (both as the operating partner and capital partner).

Artem graduated with an MA (First Class Honours) in Land Economy at the University of Cambridge and sits on the Investment and Development Committee for the Institute of Cancer Research.

An architect by training, Sally has a reputation for bringing great creativity, innovation and attention to detail to every project she works on, including some of HDR’s most high-profile education, science, workplace, and mixed-use projects around the globe. In her role as Education & Science leader, she directs and executes regional project leadership, strategic planning and business development efforts to help life science corporations and developers achieve their missions and goals.

Richard is a Director at Buro Happold and leads their UK Science & Technology Sector work. One of Richard’s current focuses is on helping research organisations to meet net-zero carbon whilst maintaining the flexible facilities that are so important in science. He has led the design of numerous major projects including The Michael Uren Biomedical Engineering Research Hub, The London Institute of Medical Sciences and is currently delivering Europe’s largest multi-let speculative laboratory building.

Kathryn has recently joined the Babraham Research Campus as Director of Science and Entrepreneurship. A scientist by training, Kathryn’s research career focussed on disease modelling and target discovery at the University of Manchester, Harvard Medical School, Wellcome Trust Sanger Institute and GlaxoSmithKline. Since then, she has established and directed various initiatives which use her passion for creating synergy and impact through academic/business and business/business partnerships. Kathryn established and led the Milner Therapeutics Institute at the University of Cambridge and spent 10 years at the NC3Rs, UKRI working with over 40 pharmaceutical companies in the US and Europe to improve scientific and business processes and reduce animal use in drug development.

She has 50+ research publications and sits on a number of national and international Review Panels including for the Innovative Medicines Initiative (IMI), BBSRC and Innovate UK. She holds an honorary Professorship with the University of Coventry where she sits on the Vice-Chancellors Advisory Group for industry/academic engagement. Kathryn works with stakeholders across the Cambridge ecosystem to support cultural change. She is a co-founder of the University of Cambridge’s Connect:Health Tech initiative which includes a thriving online community to connect entrepreneurs across disciplines.

Emma Tinsley is a leading biotech executive and the CEO of Weatherden, a global integrated clinical consultancy and experts in scientific strategy and clinical development. Emma has deep experience of company formation, clinical development strategy, operating model transformation and investment management and was previously at SV Health Investors in the biotech company creation team creating immunology and oncology companies; and prior to this, in the Life Sciences team at KPMG.

Emily Slupek is a Partner at Bidwells, with a focus on project management of R&D real estate across the

Golden Triangle of Oxford, Cambridge, and London.

She excels in delivering complex projects, with expertise in repurposing commercial spaces, labs,

offices, and mixed-use developments. Currently, she works on projects at the Harwell Campus and with

the University of Oxford.

Emily is a recognized figure in the innovation sector, regularly exploring future market trends with

speaking slots at conferences and roundtables.

Oliver is a Partner of Hawkins\Brown and one of the leading architects working in the Science and Technology sector. His experience ranges from state-of-the-art research institutes through to speculative facilities for developers. He thrives on the variety and challenge that the sector offers. Oliver’s contribution to the wider industry includes active membership and participation in several organisations, including as Chair of Designers for Science which promotes best practice and emerging trends in the sector.

Sue leads a dynamic programme of research, working closely with academics and sector

specialists. Much of her work is focused on the real estate implications of the science and

technology sector. This includes the Bidwells Life Science 2030 research programme which

encompasses a study undertaken in conjunction with YouGov investigating the location drivers

of R&D businesses.

Sue’s academic background spans the finance, planning and environmental fields. She started

her career in academia working on planning and urban design publications at the Center for

Urban Policy Research, Rutgers University, USA.

She holds an MSc in Property Investment & Finance from Bayes Business School, an MS in

Planning and Urban Policy from Rutgers University and a BSc in Rural Environment Studies.

Jonathan joined Stanhope in 2003 and leads the Property & Commercial aspects of the business, joining the Management team in 2017. He currently heads up a number of Stanhope’s major development projects.

Since joining Stanhope, Jonathan has acquired or secured a Development Management role on a number of central London office and mixed use development opportunities. In 2012, he led the acquisition of BBC Television Centre from the BBC for £200m, creating a 2.3m sq ft development opportunity. He is currently working on Television Centre Phase 2 (500 homes), Ruskin Square and a number of other projects.

Prior to joining Stanhope, Jonathan qualified as a Chartered Surveyor at Drivers Jonas and worked at Taylor Woodrow in their Central London Mixed use team.

Jon has been Strategic Director of Economy at Hammersmith and Fulham Council since 2021 and is also currently a director of the Institute of Economic Development. In Hammersmith and Fulham, he is responsible for a broad remit spanning planning, regeneration, property, housing, and economic development. Notably, Jon’s remit encompasses the borough’s partnership with Imperial College and its pioneering Industrial Strategy, which has enabled the establishment of a world-leading innovation district in White City.

Prior to joining Hammersmith and Fulham Council, Jon held a variety of roles across the civil service. He was previously Deputy Director for Regional Economic Development at the Scottish Government, and had before that been Deputy Director for Capital Investment at the Department for International Trade. As Chief Operating Officer of UK Trade & Investment’s Regeneration and Investment Organisation, Jon helped to attract institutional investment into large-scale property and infrastructure developments.

Suki Balendra a senior leader in the NHS with a 20-year background in facilitating, growing,

and promoting health research in the U.K. She has substantial, in-depth experience across

sectors including industry, academia, NHS, and central government.

She is currently the Life Sciences Lead for the clinical research network in Northwest

London. She leads the strategic work with the Life sciences industry in the region. She started

her career in the Biotechnology Industry at Abbott Diagnostics Ltd. Within a Good

manufacturing practice (GMP) environment she worked on several operational projects to

improve efficiency, cost, and reproducibility.

She focused her clinical research career within the Diabetes Research Network (DRN) at

Imperial College in a national role. The DRN was in the early stages of development when

she joined. She was integral to the setup of the network, from creating and establishing new

governance structures to working with the charity sector in creating a patient registry to

support recruitment of diabetes studies. As the Industry and portfolio lead at the DRN she had

direct responsibility for building and maintaining strategic partnerships with life science

companies with exceptional success in bringing more research opportunities in diabetes into

the U. K.

In 2018 she was seconded to the Office of Life Sciences within the Department of Business

and Industrial Strategy. where she attracted and negotiated new business to increase the UK’s

market share of health and care research activity. During the pandemic she provided

operational leadership to the NHS covid vaccine research response in Northwest London.

Suki has PhD from the University of Warwick, and she is accredited to black belt in Lean Six

Sigma. She is a passionate advocate for UK PLC as the number one destination to conduct

clinical trials.

David is an architect by training, and spent 16 years working at Arup and Arup Associates on a range of masterplans and building design projects. Before joining Arup, he spent 5 years working and studying in Japan, following a Daiwa Foundation Scholarship, working for the design department of Kajima.

He reconnected with his Japanese interests when approached by Mitsui Fudosan in 2015, and has been responsible for Mitsui's design and planning input to projects including White City Place, the new extension to the British Library, the second phase of the Television Centre development, the South Molton Street Triangle in Mayfair, and a new office development in Shoreditch in partnership with Edge Technologies. Having worked on a range of life science masterplans for Arup, including the new HQ for Astra Zeneca in Cambridge, GSK in Ulverston, and the University of Cambridge Biocentrum campus, he has continued to pursue the potential for the British Library and White City as new paradigms for life science districts. The Mitsui developments at White City and the British Library are part of a wider international initiative by Mitsui in Tokyo, Boston and San Francisco in life science cluster-forming.

Angela Kearns is a Corporate Real Estate partner in Clifford Chance's London office specialising in complex development and urban regeneration projects and their funding, direct and indirect investments and HQ occupiers work. Her work spans a broad range of asset classes including life sciences. Angela was shortlisted for Real Estate Individual (London) of the year at the Legal 500 Awards 2020 and is recognised as a Leading Individual by Legal 500 UK.

Kas Mohammed is the Vice President of the Digital Buildings division at Schneider Electric in the UK and Ireland. His team work within both new and existing buildings across Commercial Real Estate, Healthcare, Life Sciences and Education segments to deliver systems which ensure optimal efficiency and user comfort across all stages of the building life cycle. Kas is passionate about improving sustainability across the built environment and reducing carbon emissions in our sector.

Rob Burborough is a partner at 3PM with over 25 years in the science and technology sector. He is a specialist in this sector, and has led projects from all science backgrounds. Rob has collaborated extensively with science park owners in the UK and USA (including Discovery Park, Sandwich; The Oxford Science Park, Oxford; Granta Park, Great Abington; Babraham Institute, Babraham; Biomed, Granta Park, Cambridge; Chesterford Research Park, Saffron Walden).

More recently, Rob has been engaged by several organisations to advise at a strategic business case and operational execution level for private companies in respect of the investment opportunities, governance and execution strategies, and ecosystem formation for investment and future growth potential. He has been engaged to act as strategic advisor in support of the operational execution of the growth plans of venture-capital-funded private companies in the pre-revenue commercial science sector as they move from a new-company to a mature business model.

Rob has been appointed as expert panel advisor to the ISCF (Industrial Strategy Challenge Fund), focusing on core innovation and energy-efficient buildings, and is considered an industry expert in the project, programme and portfolio management of complex science and technology projects throughout the UK and globally.

Rob continues to work very closely with the UK research councils (including UK Research and Innovation, Innovate UK and the Biotechnology and Biological Sciences Research Council).